Gemcitabine + nab paclitaxel
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreas Adenocarcinoma
Conditions
Pancreas Adenocarcinoma
Trial Timeline
May 10, 2018 → Oct 16, 2024
NCT ID
NCT03377491About Gemcitabine + nab paclitaxel
Gemcitabine + nab paclitaxel is a phase 3 stage product being developed by Novocure for Pancreas Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03377491. Target conditions include Pancreas Adenocarcinoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07319910 | Pre-clinical | Active |
| NCT03377491 | Phase 3 | Completed |
Competing Products
20 competing products in Pancreas Adenocarcinoma